BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Market News

Palantir’s U.S. commercial revenue overtakes government for the first time as quarterly sales accelerate to 96% growth

Moe Alsumidaie by Moe Alsumidaie
November 3, 2026
in Market News
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

Palantir Technologies raised full-year revenue guidance to 91% growth after U.S. commercial revenue surpassed U.S. government revenue in the third quarter for the first time in the company’s history. The shift marks a structural change in the revenue mix: commercial operations grew 148% year-over-year to $984 million, while government revenue grew 96% year-over-year to $953 million.

Third-quarter total revenue reached $2.313 billion, up 96% from the prior year and 20% sequentially, crossing $2 billion in a single quarter for the first time. The company closed 212 deals valued at $1 million or more, including 64 deals of at least $10 million. Total contract value signed in the quarter was $2.918 billion, up 6% year-over-year; U.S. commercial TCV alone was $1.463 billion, up 11% year-over-year.

Palantir raised full-year 2026 revenue guidance to between $8.530 billion and $8.534 billion, representing 91% growth. The company raised U.S. commercial revenue guidance to in excess of $3.559 billion, representing growth of at least 143% for the year. Adjusted income from operations guidance was raised to between $5.245 billion and $5.249 billion, and adjusted free cash flow guidance was raised to between $4.8 billion and $5.0 billion.

What it means

The acceleration from FY2025’s 56.2% revenue growth to a 91% full-year 2026 guidance represents a material step-up in the company’s trajectory. The driver is not distributed evenly: U.S. commercial growth at 143% guidance dwarfs the overall rate, suggesting government revenue is growing but at a slower clip. The company’s U.S. commercial remaining deal value stands at $6.517 billion, up 79% year-over-year, indicating a pipeline that has expanded substantially.

BullScope TerminalYou just read Palantir Technologies Inc.’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →

The profitability picture is striking. Q3 adjusted operating margin reached 62%, compared to FY2025’s 31.6% operating margin. The company generated $1.216 billion in adjusted free cash flow in the quarter alone, a 53% margin on revenue. This suggests either a material shift in contract mix toward higher-margin business, or a step-change in operational leverage as the installed base scales. The document does not specify which.

The open question is whether commercial growth at this pace is sustainable or represents a comparison effect against a weak prior-year base. The company does not disclose year-over-year commercial revenue figures for Q3 2025, making it impossible to assess whether the 148% growth reflects a low starting point or genuine acceleration in the commercial motion. Similarly, the document does not explain whether the margin expansion reflects pricing power, product mix, or a one-time benefit from deal timing.

What to watch

The Q4 2026 guidance window will test whether the commercial momentum persists. The company guided Q4 revenue to between $2.649 billion and $2.653 billion, implying roughly 20% sequential growth from Q3. If Q4 lands in that range, the full-year 91% growth guidance holds; a miss would signal either a slowdown in commercial bookings or a shift in deal timing. The next quarterly filing will also reveal whether U.S. commercial revenue maintains its lead over government revenue or whether the crossover was a one-quarter event.

Source: the company’s 8-K filed 2026-11-02 with the SEC.

BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.

For the standing yardsticks on Palantir Technologies: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Palantir Technologies.

BullScope TerminalYou just read Palantir Technologies Inc.’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Zoetis narrows revenue outlook as U.S. companion animal sales slide, raises profit guidance on margin strength

by Moe Alsumidaie
November 6, 2026
0

Zoetis cut its full-year revenue forecast to $9.220 billion to $9.320 billion, representing organic operational decline of 2 percent to 1 p

Read moreDetails

Viatris Raises 2026 Guidance as Adjusted EBITDA Climbs 9 Percent Year to Date

by Moe Alsumidaie
November 6, 2026
0

Viatris raised the midpoints of its full-year 2026 financial guidance across all key metrics on the strength of nine-month adjusted EBITDA

Read moreDetails

Joby Aviation raises FY26 revenue outlook 15% as eIPP flights and defense contracts accelerate path to certification

by Moe Alsumidaie
November 5, 2026
0

Joby Aviation lifted its full-year 2026 revenue guidance by 15 percent and completed the first crewed eVTOL flights under the federal gover

Read moreDetails

Amgen’s revenue growth slows to 8% as biosimilar competition erodes legacy franchises

by Moe Alsumidaie
November 4, 2026
0

Amgen's third-quarter revenue rose 8% to $10.4 billion, a deceleration from the 10.0% full-year growth rate filed for fiscal 2025. The slow

Read moreDetails

Regeneron’s revenue surges 36 percent as Dupixent and EYLEA HD drive record quarter

by Moe Alsumidaie
November 2, 2026
0

Regeneron's third-quarter revenue jumped to $5,116 million, a 36 percent increase from $3,754 million in the same quarter last year, powere

Read moreDetails
Next Post

Xeris Biopharma: A Company That Just Turned Profitable Is Being Priced Like One That Always Was

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Target’s Revenue Has Shrunk for Three Straight Years. Its Stock Just Hit a 52-Week High.

August 14, 2026

Gilead at Its All-Time High: Three Claims the Filings Put to the Test

November 2, 2026

JPMorgan Chase’s third-quarter profit falls 28 percent as revenue slumps and credit costs rise

October 14, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.